Morgan Stanley’s Marker Therapeutics MRKR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2 | Hold |
2
| – | – | ﹤0.01% | 8388 |
|
|
2026
Q1 | $2 | Sell |
2
-13
| -87% | -$21 | ﹤0.01% | 8264 |
|
|
2025
Q4 | $22 | Sell |
15
-446
| -97% | -$505 | ﹤0.01% | 8067 |
|
|
2025
Q3 | $412 | Buy |
461
+60
| +15% | +$74 | ﹤0.01% | 7520 |
|
|
2025
Q2 | $613 | Buy |
401
+8
| +2% | +$10 | ﹤0.01% | 7408 |
|
|
2025
Q1 | $483 | Buy |
393
+35
| +10% | +$64 | ﹤0.01% | 7376 |
|
|
2024
Q4 | $1.11K | Sell |
358
-3,050
| -89% | -$10.8K | ﹤0.01% | 7259 |
|
|
2024
Q3 | $9.61K | Hold |
3,408
| – | – | ﹤0.01% | 6727 |
|
|
2024
Q2 | $18.5K | Sell |
3,408
-632
| -16% | -$2.69K | ﹤0.01% | 6492 |
|
|
2024
Q1 | $17.4K | Buy |
4,040
+442
| +12% | +$1.93K | ﹤0.01% | 6533 |
|
|
2023
Q4 | $19.8K | Buy |
3,598
+1,658
| +85% | +$5.62K | ﹤0.01% | 6447 |
|
|
2023
Q3 | $8.81K | Hold |
1,940
| – | – | ﹤0.01% | 6776 |
|
|
2023
Q2 | $6.01K | Hold |
1,940
| – | – | ﹤0.01% | 6944 |
|
|
2023
Q1 | $1.38K | Buy |
1,940
+31
| +2% | +$74 | ﹤0.01% | 7300 |
|
|
2022
Q4 | $5.08K | Buy |
1,909
+1
| +0.1% | +$3 | ﹤0.01% | 7141 |
|
|
2022
Q3 | $7K | Sell |
1,908
-1
| -0.1% | -$4 | ﹤0.01% | 7181 |
|
|
2022
Q2 | $6K | Sell |
1,909
-375
| -16% | -$1.25K | ﹤0.01% | 7363 |
|
|
2022
Q1 | $10K | Sell |
2,284
-1,096
| -32% | -$6.26K | ﹤0.01% | 7403 |
|
|
2021
Q4 | $32K | Sell |
3,380
-254
| -7% | -$3.37K | ﹤0.01% | 7009 |
|
|
2021
Q3 | $61K | Sell |
3,634
-1,489
| -29% | -$30.5K | ﹤0.01% | 6629 |
|
|
2021
Q2 | $143K | Buy |
5,123
+3,587
| +234% | +$94.4K | ﹤0.01% | 6180 |
|
|
2021
Q1 | $34K | Sell |
1,536
-1,499
| -49% | -$34.3K | ﹤0.01% | 6525 |
|
|
2020
Q4 | $43K | Buy |
3,035
+2,652
| +692% | +$41.2K | ﹤0.01% | 6203 |
|
|
2020
Q3 | $6K | Sell |
383
-715
| -65% | -$13K | ﹤0.01% | 6411 |
|
|
2020
Q2 | $23K | Buy |
1,098
+452
| +70% | +$9.88K | ﹤0.01% | 5973 |
|
|
2020
Q1 | $12K | Sell |
646
-18,086
| -97% | -$461K | ﹤0.01% | 5974 |
|
|
2019
Q4 | $540K | Buy |
18,732
+3,794
| +25% | +$138K | ﹤0.01% | 4884 |
|
|
2019
Q3 | $764K | Buy |
14,938
+14,505
| +3,350% | +$857K | ﹤0.01% | 4452 |
|
|
2019
Q2 | $34K | Sell |
433
-685
| -61% | -$40.7K | ﹤0.01% | 5755 |
|
|
2019
Q1 | $73K | Buy |
1,118
+594
| +113% | +$34.7K | ﹤0.01% | 5521 |
|
|
2018
Q4 | $29K | Buy |
524
+187
| +55% | +$13.6K | ﹤0.01% | 5933 |
|
|
2018
Q3 | $30K | Sell |
337
-66
| -16% | -$5.67K | ﹤0.01% | 6026 |
|
|
2018
Q2 | $38K | Buy |
403
+377
| +1,450% | +$19.2K | ﹤0.01% | 5985 |
|
|
2018
Q1 | $1K | Buy |
26
+25
| +2,500% | +$883 | ﹤0.01% | 6543 |
|
|
2017
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6616 |
|
|
2017
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6576 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 6623 |
|
|
2017
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6592 |
|
|
2016
Q4 | $0 | Buy |
+1
| New | +$47 | ﹤0.01% | 6541 |
|
Other funds holding MRKR
NMC
BOCH
ACM
CIA
Morgan Stanley's MRKR Position: Q2 2026 in Review
Morgan Stanley held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8388.
Morgan Stanley first reported a position in MRKR in Q4 2016 and has held it in 39 quarters since. The position peaked at $764K in Q3 2019. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.
- Morgan Stanley held 2 shares of Marker Therapeutics worth $2 as of Q2 2026.
- Morgan Stanley left its Marker Therapeutics share count unchanged in Q2 2026.
- Marker Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8388 holding.
- Morgan Stanley first reported a position in Marker Therapeutics in Q4 2016 and has held it in 39 quarters since.
- Morgan Stanley's Marker Therapeutics position peaked at $764K in Q3 2019.
- 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.